ReviewFrontiers in microbiology2025
Regulatory mechanisms of the gut microbiota-short chain fatty acids signaling axis in slow transit constipation and progress in multi-target interventions.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The endocannabinoidome-microbiota axis in obesity: a potential link to colorectal cancer development.Journal of physiology and biochemistry · 2026Review
- Dose-Dependent Commercial Probiotic Intervention Modulates Gut Microbiota and Fecal Metabolome Associated with Improved Intestinal Function in a Loperamide-Induced Constipation Rat Model.Probiotics and antimicrobial proteins · 2026Article
- Dietary Supplementation with Hesperidin and Rosmarinic Acid Improves Meat Quality, Modulates Gut Microbiota, and Enhances Antioxidant Capacity in Finishing Pigs.Microorganisms · 2026Article
- Antibiotic Exposure and Periodontal Susceptibility: A Risk-Modifying Hypothesis.International journal of molecular sciences · 2026Review
- Acerola and Its By-Products as Sources of Bioactive Compounds: Phytochemical Profile and Biological Effects in Experimental and Clinical Studies.Molecules (Basel, Switzerland) · 2026Review
- Live and Heat-InactivatedNutrients · 2026Article
- Postbiotics and paraprobiotics in food biochemistry mechanisms stability and nutritional applications.NPJ science of food · 2026Review
- Gut Microbiome Dysregulation Across Schizophrenia Spectrum Disorders: Bacteria-, Fungi- and Virome-Level Alterations with Molecular and Immunological Implications.International journal of molecular sciences · 2026Review
- Microbiota-immune crosstalk in the regulation of intestinal motility in constipation.Frontiers in microbiology · 2026Review
- Article
- Gastrointestinal symptoms and the Mediterranean dietary pattern: secondary analysis of a randomized controlled trial in a population with increased cardiometabolic risk.Frontiers in nutrition · 2026Article
- Mechanisms by which complex carbohydrates influence immune imbalance in COPD via the gut-lung axis: from colonic fermentation to pulmonary immune responses.Frontiers in nutrition · 2026Review
- Probiotics in irritable bowel syndrome: strain-specific effects, diet, and biomarker timing.Frontiers in cellular and infection microbiology · 2026Article
- Microbiota-immune-enteric nervous system interactions in functional constipation: a narrative review and hypothesis-generating framework.Frontiers in immunology · 2026Review
- Gut microbiota dysbiosis-induced chronic inflammation as a driver of atherosclerosis: cellular crosstalk and host-microbe interactions.Frontiers in cellular and infection microbiology · 2026Review
- The microbiome as a systems-level regulator of immune, metabolic, neural, and endocrine signaling in cancer.Frontiers in immunology · 2026Review
- Probiotics and iron bioavailability: mechanisms, clinical evidence, and translational applications-a comprehensive review of the probiotic strainFrontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Slow-transit constipation (STC) is an increasingly prevalent disorder that imposes a substantial health and economic burden. Mounting evidence highlights the "gut microbiota-short-chain fatty acid (SCFA)-motility" axis as a central pathophysiological link between dysbiosis and impaired colonic transit. This review synthesizes current knowledge of how SCFAs, especially acetate, propionate and butyrate, shape motility through serotonergic signaling, enteric nervous system modulation, epithelial barrier integrity and immune regulation. Particular attention is devoted to the biased-signaling properties of the SCFA receptors FFAR2 and FFAR3 (free fatty acid receptors 2 and 3, respectively), including emerging data on their heterodimerization. The article then appraises recent randomized controlled trials and meta-analyses of multi-target interventions (dietary fibers, synbiotics, postbiotics, fecal microbiota transplantation, phytochemicals, and small-molecule FFAR agonists) highlighting their efficacy, safety, and translational hurdles. Finally, the authors propose a precision-medicine framework that integrates multi-omics microbiome profiling, metabolomics, and host genetics to enable phenotype-stratified therapy. Key research gaps include limited long-term safety data, heterogeneous human cohorts and the need for large multicenter trials and machine-learning-guided responder prediction. Collectively, the review provides a roadmap for shifting STC management from symptom control to mechanism-based, personalized care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.